Havel et al. concluded that tumor genomics, host germline genetics, PD-L1 level, and the intrinsic features of the tumor microenvironment, as well as the gut microbiome, may be the main reasons for such low response to ICI therapy (Havel et al., 2019). The gene discussed is CD274; the disease is neoplasm.